Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer

Several polymorphisms in the vitamin D receptor ( VDR ) gene have been implicated as risk factors for prostate cancer. We performed a meta-analysis of 14 studies (17 comparisons) with TaqI genotyping (1870 prostate cancer cases; 2843 controls), 6 studies (8 comparisons) with poly(A) repeat genotyping (540 cases; 870 controls), 5 studies with BsmI genotyping (987 cases; 1504 controls), and 3 studies with FokI genotyping (514 cases; 545 controls). The random-effects odds ratio (OR) for the t versus T allele was 0.95 [95% confidence interval (CI), 0.86–1.05]. There was no suggestion of an overall effect either in recessive or dominant modeling, and the comparison of t/t versus T/T also showed no differential prostate cancer susceptibility (OR, 0.88; 95% CI, 0.70–1.10). No effect of t was seen in subjects of European descent (nine comparisons; OR, 0.97; 95% CI, 0.87–1.08), Asian descent (five comparisons; OR, 0.88; 95% CI, 0.66–1.17), or African descent (three comparisons; OR, 0.94; 95% CI, 0.41–2.17). There was no between-study heterogeneity in any of these analyses. Overall, the random effects OR was 0.94 (95% CI, 0.75–1.18; no between-study heterogeneity) for the S versus L allele, 0.92 (95% CI, 0.63–1.35; P < 0.01 for heterogeneity) for the B versus b allele, and 1.03 (95% CI, 0.86–1.23; no between-study heterogeneity) for the f versus F allele. The meta-analysis shows that these four polymorphisms are unlikely to be major determinants of susceptibility to prostate cancer on a wide population basis.

[1]  M. Hakama,et al.  Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) , 2000, Cancer Causes & Control.

[2]  L. Kolonel,et al.  Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States) , 1998, Cancer Causes & Control.

[3]  K. Helzlsouer,et al.  Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States) , 1995, Cancer Causes & Control.

[4]  J. Ioannidis,et al.  SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[5]  H. Yamanaka,et al.  Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population , 2003, International journal of urology : official journal of the Japanese Urological Association.

[6]  John P A Ioannidis,et al.  Genetic associations: false or true? , 2003, Trends in molecular medicine.

[7]  H. McLeod,et al.  CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia , 2003, British Journal of Cancer.

[8]  Thomas A Trikalinos,et al.  Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.

[9]  J. Ioannidis,et al.  Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  T. Stamey,et al.  Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  J. Reichardt,et al.  Hormones and prostate cancer: Current perspectives and future directions , 2002, The Prostate.

[12]  D. Pinto,et al.  The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population , 2002, Journal of Human Genetics.

[13]  J. Stanford,et al.  Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  John P A Ioannidis,et al.  Commentary: meta-analysis of individual participants' data in genetic epidemiology. , 2002, American journal of epidemiology.

[15]  M. Marberger,et al.  Vitamin D receptor gene polymorphism and prostate cancer risk , 2002, The Prostate.

[16]  T. Katoh,et al.  Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. , 2001, Endocrine journal.

[17]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[18]  R. Strange,et al.  Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes , 2001, British Journal of Cancer.

[19]  R. Strange,et al.  Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes. , 2001, Carcinogenesis.

[20]  J. Fraumeni,et al.  Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. , 2001, Cancer research.

[21]  M. Marberger,et al.  Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. , 2001, Urology.

[22]  J. Stanford,et al.  Familial prostate cancer. , 2001, Epidemiologic reviews.

[23]  N. Makridakis,et al.  Molecular epidemiology of hormone-metabolic loci in prostate cancer. , 2001, Epidemiologic reviews.

[24]  J. Stanford,et al.  Genetics of prostate cancer: too many loci, too few genes. , 2000, American journal of human genetics.

[25]  L. Kiemeney,et al.  Polymorphisms in the Vitamin D Receptor Gene and the Androgen Receptor Gene and the Risk of Benign Prostatic Hyperplasia , 2000, European Urology.

[26]  T. Habuchi,et al.  Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. , 2000, Cancer research.

[27]  Jack A. Taylor,et al.  Vitamin D receptor polymorphisms and prostate cancer , 2000, Molecular carcinogenesis.

[28]  M. Murata,et al.  Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. , 1999, Anticancer research.

[29]  W. Vogel,et al.  Vitamin D receptor polymorphisms as markers in prostate cancer , 1999, Human Genetics.

[30]  Y. Furuya,et al.  Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer. , 1999, Endocrine journal.

[31]  J. Ioannidis,et al.  Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. , 1999, Journal of clinical epidemiology.

[32]  P. Malloy,et al.  The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of FokI Variants , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  A. Kibel,et al.  Vitamin D receptor polymorphisms and lethal prostate cancer. , 1998, The Journal of urology.

[34]  G. Coetzee,et al.  Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. , 1998, Cancer research.

[35]  P. Malloy,et al.  Vitamin D receptor gene polymorphisms: analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. , 1998, Biochemical and biophysical research communications.

[36]  J. Ioannidis,et al.  Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.

[37]  H. Koeffler,et al.  Vitamin D receptor: no evidence for allele-specific mRNA stability in cells which are heterozygous for the Taq I restriction enzyme polymorphism. , 1997, Biochemical and biophysical research communications.

[38]  G. Coetzee,et al.  Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. , 1997, Journal of the National Cancer Institute.

[39]  J. Mohler,et al.  Association of prostate cancer with vitamin D receptor gene polymorphism. , 1996, Cancer research.

[40]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[41]  T. Stamey,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.

[42]  J. Eisman,et al.  Prediction of bone density from vitamin D receptor alleles , 1994, Nature.

[43]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[44]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.

[45]  M. Lucia,et al.  The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. , 1992, Cancer research.

[46]  I. Yokota,et al.  A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single-strand conformation polymorphism analysis for heterozygous carrier detection. , 1991, American journal of human genetics.

[47]  Schwartz Gg,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990 .

[48]  J. Shine,et al.  Cloning and expression of full-length cDNA encoding human vitamin D receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.